Drug Trial Radar · NCT07791160
Study of Acoramidis in Patients With Transthyretin Amyloid Cardiomyopathy
Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Sep 7, 2026
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- Collaborators
- Saving Lives Matters; Heart's Foundation
- First posted
- Aug 27, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive heart disease caused by the buildup of an abnormal protein, called transthyretin (TTR), in the heart. This buildup can make it harder for the heart to pump blood and may lead to worsening symptoms over time. Acoramidis is a medicine approved for the treatment of adults with wild-type or hereditary (variant) ATTR-CM. While its benefits have been demonstrated in clinical trials, more information is needed about how it is used and how patients do in everyday medical practice. The MOSAIC-TTR study is an observational study in France. Participants will receive acoramidis as part of their usual medical care. No experimental treatments or additional medical procedures will be required. The study will collect information directly from participating hospitals and from the Healthcare European Amyloidosis Registry (HEAR; NCT05101304). The main goal of the study is to understand how patients' quality of life, daily functioning, and overall well-being change during the first 12 months of treatment with acoramidis, using questionnaires completed by the patients themselves. The study will also collect information about the characteristics of patients receiving acoramidis, how the medicine is used in routine clinical practice, and its safety and tolerability. The information collected will help improve the understanding of ATTR-CM and may help improve the care of people living with this condition.
Conditions
- Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Interventions
AcoramidisDrug
356 mg film-coated tablets. The recommended dose is 712 mg (two tables, 356 mg) orally twice daily, corresponding to a total daily dose of 1424 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patient Reported Outcome Measure: Amylo-AFFECT-QOL scoreTime frame: At 3, 6, 9, and 12 months after initiation of acoramidis
- Patient Reported Outcome Measure: KCCQ-23 scoreTime frame: At 3, 6, 9, and 12 months after initiation of acoramidis
- Patient Reported Outcome Measure: EQ-5D-3L index scoreTime frame: At 3, 6, 9, and 12 months after initiation of acoramidis
- Patient Reported Outcome Measure: EQ VAS scoreTime frame: At 3, 6, 9, and 12 months after initiation of acoramidis
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Many locations
Many Locations, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.